Spinal muscular atrophy: history and current treatment landscape
Open Access
- 21 August 2026
- journal article
- Published by The International Child Neurology Association in Journal of the International Child Neurology Association
- Vol. 1 (1)
Abstract
In recent years, pediatric neurology has witnessed significant advances in the development of disease-modifying therapies, with spinal muscular atrophy (SMA) emerging as one of the most impactful conditions in this field. This article provides a comprehensive overview of the history of SMA, highlighting its evolving classification and the genetic basis underlying its clinical variability. Moreover, it outlines the development and clinical trial data of the three Food and Drug Administration- and European Medicines Agency-approved therapies: nusinersen, onasemnogene abeparvovec, and risdiplam. These treatments have shifted SMA from a fatal diagnosis to a treatable condition, especially when initiated presymptomatically. Finally, the article discusses future directions, including combination therapies, novel pharmacological targets, biomarker development, and the need for ethical and equitable access to treatment worldwide. With ongoing research, SMA continues to serve as a paradigm for progress in neuromuscular medicine and the potential of personalized, gene-targeted therapies.Keywords
This publication has 43 references indexed in Scilit:
- An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapiesEuropean Journal of Paediatric Neurology, 2024
- Combination disease‐modifying treatment in spinal muscular atrophy: A proposed classificationAnnals of Clinical and Translational Neurology, 2023
- Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study dataEuropean Journal of Paediatric Neurology, 2022
- Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophyMuscle & Nerve, 2021
- Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case SeriesThe Journal of Pediatrics, 2021
- European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophyEuropean Journal of Paediatric Neurology, 2020
- Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular AtrophyJAMA Pediatrics, 2018
- Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy numberHuman Genetics, 2006
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995
- Chaos in classification of the spinal muscular atrophies of childhoodNeuromuscular Disorders, 1991